{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:21:13Z","timestamp":1783657273381,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Verrica Pharmacueticals Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40257-020-00570-8","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T15:47:09Z","timestamp":1613749629000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w\/v) for the Treatment of Molluscum Contagiosum"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-9905","authenticated-orcid":false,"given":"Elaine","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-420X","authenticated-orcid":false,"given":"Pearl","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Willson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-5278","authenticated-orcid":false,"given":"Melissa","family":"Olivadoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"570_CR1","doi-asserted-by":"crossref","unstructured":"Bugert J. Genus molluscipoxvirus. Poxviruses Birkh\u00e4user advances in infectious diseases: Birkhauser Basel; 2007. pp. 89\u2013112.","DOI":"10.1007\/978-3-7643-7557-7_5"},{"issue":"6","key":"570_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1525-1470.2006.00313.x","volume":"23","author":"D Hanna","year":"2006","unstructured":"Hanna D, Hatami A, Powell J, Marcoux D, Maari C, Savard P, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol. 2006;23(6):574\u20139.","journal-title":"Pediatr Dermatol."},{"issue":"2","key":"570_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/fampra\/cmt075","volume":"31","author":"JR Olsen","year":"2014","unstructured":"Olsen JR, Gallacher J, Piguet V, Francis NA. Epidemiology of molluscum contagiosum in children: a systematic review. Fam Pract. 2014;31(2):130\u20136.","journal-title":"Fam Pract."},{"issue":"2","key":"570_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1473-3099(14)71061-8","volume":"15","author":"AKC Leung","year":"2015","unstructured":"Leung AKC. The natural history of molluscum contagiosum in children. Lancet Infect Dis. 2015;15(2):136\u20137.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"570_CR5","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Investig Dermatol. 2014;134(6):1527\u201334.","journal-title":"J Investig Dermatol."},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/bs.aivir.2014.11.004","volume":"92","author":"JL Shisler","year":"2015","unstructured":"Shisler JL. Immune evasion strategies of molluscum contagiosum virus. Adv Virus Res. 2015;92:201\u201352.","journal-title":"Adv Virus Res."},{"issue":"10","key":"570_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1473-3099(13)70109-9","volume":"13","author":"X Chen","year":"2013","unstructured":"Chen X, Anstey AV, Bugert JJ. Molluscum contagiosum virus infection. Lancet Infect Dis. 2013;13(10):877\u201388.","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"570_CR8","first-page":"191","volume":"102","author":"NB Silverberg","year":"2018","unstructured":"Silverberg NB. Molluscum contagiosum virus infection can trigger atopic dermatitis disease onset or flare. Cutis. 2018;102(3):191\u20134.","journal-title":"Cutis"},{"issue":"3","key":"570_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1067\/mjd.2000.106370","volume":"43","author":"NB Silverberg","year":"2000","unstructured":"Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol. 2000;43(3):503\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"570_CR10","first-page":"301","volume":"104","author":"NB Silverberg","year":"2019","unstructured":"Silverberg NB. Pediatric molluscum: an update. Cutis. 2019;104(5):301\u20135 (E1; E2).","journal-title":"Cutis"},{"issue":"10","key":"570_CR11","doi-asserted-by":"publisher","first-page":"e76948","DOI":"10.1371\/journal.pone.0076948","volume":"8","author":"CM Hughes","year":"2013","unstructured":"Hughes CM, Damon IK, Reynolds MG. Understanding U.S. healthcare providers\u2019 practices and experiences with molluscum contagiosum. PLoS ONE. 2013;8(10):e76948.","journal-title":"PLoS ONE"},{"issue":"8","key":"570_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2165\/00148581-200305080-00001","volume":"5","author":"N Silverberg","year":"2003","unstructured":"Silverberg N. Pediatric molluscum contagiosum: optimal treatment strategies. Paediatr Drugs. 2003;5(8):505\u201312.","journal-title":"Paediatr Drugs."},{"issue":"2","key":"570_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1473-3099(14)71053-9","volume":"15","author":"JR Olsen","year":"2015","unstructured":"Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15(2):190\u20135.","journal-title":"Lancet Infect Dis."},{"key":"570_CR14","first-page":"CD004767","volume":"5","author":"JC van der Wouden","year":"2017","unstructured":"van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van der Suijlekom-Smit LW, Koning S. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017;5:CD004767.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"570_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/pde.13228","volume":"34","author":"E Forbat","year":"2017","unstructured":"Forbat E, Al-Niaimi F, Ali FR. Molluscum contagiosum: review and update on management. Pediatr Dermatol. 2017;34(5):504\u201315.","journal-title":"Pediatr Dermatol."},{"issue":"8","key":"570_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ijd.14079","volume":"57","author":"AK Guzman","year":"2018","unstructured":"Guzman AK, Schairer DO, Garelik JL, Cohen SR. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. Int J Dermatol. 2018;57(8):1001\u20136.","journal-title":"Int J Dermatol."},{"issue":"2","key":"570_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/0009922808326085","volume":"48","author":"S Cathcart","year":"2009","unstructured":"Cathcart S, Coloe J, Morrell DS. Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. Clin Pediatr (Phila). 2009;48(2):161\u20135.","journal-title":"Clin Pediatr (Phila)."},{"issue":"2","key":"570_CR18","first-page":"27","volume":"12","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Kircik L. Topical cantharidin in the management of molluscum contagiosum: preliminary assessment of an ether-free, pharmaceutical-grade formulation. J Clin Aesthet Dermatol. 2019;12(2):27\u201330.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"6","key":"570_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2013.01.009","volume":"68","author":"DT Pompei","year":"2013","unstructured":"Pompei DT, Rezzadeh KS, Viola KV, Lee DH, Schairer DO, Chismar LA, et al. Cantharidin therapy: practice patterns and attitudes of health care providers. J Am Acad Dermatol. 2013;68(6):1045\u20136.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"570_CR20","first-page":"JOS0220","volume":"19","author":"V Agnetta","year":"2020","unstructured":"Agnetta V, Torres A, Desai S, Hebert A, Kircik L. Compounding in dermatology update. J Drugs Dermatol. 2020;19(2):JOS0220.","journal-title":"J Drugs Dermatol."},{"key":"570_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3238","author":"LF Eichenfield","year":"2020","unstructured":"Eichenfield LF, McFalda W, Brabec B, Siegfried E, Kwong P, McBride M, Rieger J, Willson C, Davidson M, Burnett P. Safety and efficacy of VP-102, a proprietary drug-device combination product containing cantharidin, 0.7% (w\/v), in children and adults with molluscum contagiosum: two phase 3 randomized, double-blind, vehicle-controlled trials. JAMA Dermatol. 2020. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3238.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"570_CR22","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1177\/0269216308094102","volume":"22","author":"JT van der Steen","year":"2008","unstructured":"van der Steen JT, Kruse RL, Szafara KL, Mehr DR, van der Wal G, Ribbe MW, et al. Benefits and pitfalls of pooling datasets from comparable observational studies: combining US and Dutch nursing home studies. Palliat Med. 2008;22(6):750\u20139.","journal-title":"Palliat Med."},{"issue":"4","key":"570_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jaad.2019.09.064","volume":"82","author":"AA Hebert","year":"2020","unstructured":"Hebert AA, Siegfried EC, Durham T, de Leon EN, Reams T, Messersmith E, et al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: a randomized clinical trial. J Am Acad Dermatol. 2020;82(4):887\u201394.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"570_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1525-1470.2012.01810.x","volume":"31","author":"J Coloe Dosal","year":"2014","unstructured":"Coloe Dosal J, Stewart PW, Lin JA, Williams CS, Morrell DS. Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. Pediatr Dermatol. 2014;31(4):440\u20139.","journal-title":"Pediatr Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00570-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T06:19:50Z","timestamp":1616048390000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00570-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00570-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"19 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Trials were supported by Verrica Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lawrence F. Eichenfield, MD, received funds for research to his institution as a study center and consulting fees and stock options from Verrica Pharmaceuticals Inc. He is also on the board of directors for Verrica Pharmaceuticals Inc. Elaine Siegfried, MD, received funds for research to her institution as a study center and consulting fees from Verrica Pharmaceuticals Inc. She has also received consulting fees and funds as a research center for Novan. Pearl Kwong, MD, received funds for research as a study center and consulting fees from Verrica Pharmaceuticals Inc. Mark McBride, PhD, was paid as a consultant to run analyses on the statistics for the study by Verrica Pharmaceuticals Inc. Dr. McBride is also a consultant for Novan. Jayson Rieger, PhD, was an employee of Verrica Pharmaceuticals, holds company stock from Verrica Pharmaceuticals Inc., and holds a patent related to the work. David Glover, PhD, is an employee of PBM Capital Group. Cynthia Willson, RN, BSN, is an employee of Verrica Pharmaceuticals and holds company stock. Matthew Davidson, PhD, was an employee of, received personal fees from, and holds stock of Verrica Pharmaceuticals Inc. He also holds patents related to the research. Patrick Burnett, MD, PhD, was an employee of Verrica Pharmaceuticals and holds company stock. Melissa Olivadoti, PhD, is an employee of Verrica Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: MD, JR, ES, CW, DG. Methodology: MD, JR, MM, DG. Formal analysis and investigation: MD, JR, MM, PB, CW, LE, ES, PK. Writing\u2014original draft preparation: MO. Writing\u2014review and editing: JR, MD, MM, PB, CW, LE, ES, PK, DG, MO. Funding acquisition: JR, MD. Supervision: PB, CW, JR, DG, MD.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Local institutional review boards or ethics committees at each trial center approved the protocol and consent form, oversaw trial conduct, and maintained documentation.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the 17 adult participants and the parents or guardians of participants aged <\u00a018 years as per the local state regulations.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as no patient-related data were used.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}